 | Up a level |
Journal Article
Johnson, M. L., Gort, E., Pant, S., Lolkema, M. P., Sebastian, M., Scheffler, M., Hwang, J., Duenzinger, U., Riemann, K., Kitzing, T. and Janne, P. A. (2021). A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis. Ann. Oncol., 32. S. S591 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Johnson, M. L., de langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Okamoto, I., Kim, S-W., Linardou, H., Novello, S., Chen, Y., Solomon, B., Obiozor, C., Wang, Y. and Paz-Ares, L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann. Oncol., 33 (7). S. S1417 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041